Development of oligodendrocytes, myelin-forming glia in the central nervous system (CNS), proceeds on a protracted schedule. Specification of oligodendrocyte progenitors (OLPs) begins early in development, whereas their terminal differentiation occurs at late embryonic and postnatal periods. How these distinct steps are controlled remains unclear. Our previous study demonstrated an important role of the helix-loop-helix (HLH) transcription factor Ascl1 in early generation of OLPs in the developing spinal cord.
INTRODUCTION
Oligodendrocytes are the major constituent of myelin in the vertebrate CNS, and play important roles in its formation and function (Raff, 1989) . Although myelin is formed mostly in the postnatal period in mammals, specification of oligodendrocytes occurs relatively early during development (Noble et al., 2004; Richardson et al., 2006) . Early cells in the oligodendrocyte lineage retain the capacity of cell divisions, and thus are called oligodendrocyte progenitors (OLPs) (Barres and Raff, 1994) . OLPs are first specified from multipotent progenitors in the ventricular zone (VZ) located on the inner side of the developing neural tube. These specified OLPs subsequently migrate to the forming outer layer called the mantle zone (MZ) and spread throughout the CNS parenchyma . These migratory OLPs remain undifferentiated until the perinatal period, and begin to undergo terminal differentiation and express myelin genes mostly in the postnatal period. Thus, oligodendrocyte development occurs on a protracted time course.
Recent studies have revealed that each of these steps occurs at distinct stages in different regions. For example, OLPs in the developing spinal cord had long been thought to arise from a restricted ventral progenitor domain (Rowitch, 2004; Richardson et al., 2006) . It has recently been shown, however, that OLPs arise in multiple progenitor domains along the dorsoventral axis at distinct developmental stages (Spassky et al., 1998; Liu et al., 2003; Cai et al., 2005; Vallstedt et al., 2005; Fogarty et al., 2005; Sugimori et al., 2007) . Recent studies have also demonstrated multiple origins of oligodendrocytes in the developing forebrain Yue et al., 2006) . In the spinal cord, these specified OLPs express either Nkx2-2 or Olig2, thereby comprising two molecularly distinct populations at early stages (Lu et al., 2002; Zhou and Anderson, 2002; Fu et al., 2002; Liu and Rao, 2004; Danesin et al., 2006; Sugimori et al., 2007) . The terminal differentiation of these OLPs also occurs at specific stages in distinct regions. In the rodent spinal cord, myelin gene expression is initiated in the dorsal and ventral regions near the midline around birth (Fu et al., 2002; Wang et al., 2006) . Subsequently, it spreads laterally along the forming white matter, and then gradually proceeds in the inner gray matter postnatally. Thus, both specification and terminal differentiation of oligodendrocytes are under precise spatiotemporal control.
Previous studies have demonstrated that multiple classes of transcription factors are involved in this process. They include the HLH factors Olig1 and Olig2 (Lu et al., 2002; Zhou and Anderson, 2002; Takebayashi et al., 2002) , Ascl1 (Kondo and Raff, 2000a; Wang et al., 2001; Parras et al., 2004; Parras et al., 2007; Gokhan et al., 2005; Sugimori et al., 2007) , and Id2, Id4 and Hes5 (Kondo and Raff, 2000b; Wang et al., 2001; Samanta and Kessler, 2004; Liu et al., 2006) , the homeodomain factors Nkx2-2 and Dlx1/2 (Qi et al., 2001; Fu et al., 2002; Liu et al., 2007; Petryniak et al., 2007) , zincfinger factor Zfp488 (Wang et al., 2006) , and multiple members of the Sox family (Stolt et al., 2002; Stolt et al., 2003; Stolt et al., 2004; Stolt et al., 2006; Sohn et al., 2006) . How these molecules control the timing of oligodendrocyte development, however, is not yet fully understood. Our recent studies have shown that Ascl1 controls specification of OLPs at an early embryonic stage in the spinal cord and forebrain Parras et al., 2007) . Interestingly, recent studies have shown that Ascl1 is also expressed in postnatal and adult OLPs Aguirre et al., 2007; Kim et al., 2007) . Its in vivo role in oligodendrocyte development, however, remains unclear. Here, we show that Ascl1 plays an important role in differentiation of OLPs into myelin-expressing oligodendrocytes at late embryonic stages in the spinal cord.
MATERIALS AND METHODS

Animals
All animal procedures were performed according to the guidelines and regulations of the Institutional Animal Care and Use Committee and the National Institute of Health. The maintenance and genotyping of Ascl1 -/- (Parras et al., 2002) and Ascl1::GFP mice (Gong et al., 2003) were described previously . Embryos and pups of the wild-type and mutant mice and Sprague-Dawley rats were collected from timed-pregnant females.
Immunostaining
Rabbit anti-Nkx2-2 and guinea pig anti-Olig2 antibodies were kind gifts from Dr T. Jessell at Columbia University. Mouse monoclonal antibody for Nkx2-2 was obtained from the Developmental Studies Hybridoma Bank at the Iowa University. Rabbit antibodies for Ascl1, Olig1, Olig2 and Pax6 have been described previously (Mizuguchi et al., 2001) . Antibodies for following antigens were purchased from commercial sources: Ascl1, platelet-derived growth factor receptor ␣ (PDGFR␣) and activated caspase 3 (BD Bioscience); O4, galactocerebroside (GalC), NG2 (chondroitin sulfate proteoglycan 4, Cspg4), myelin basic protein (MBP) and myelinassociated glycoprotein (MAG) (Millipore); 2Ј,3Ј-cyclic-nucleotide 3Јphosphodiesterase (CNP; CNP1) and glial fibrillary acidic protein (GFAP) (Sigma-Aldrich); ␤-tubulin type III (TuJ1) (Babco); Sox10 (Santa Cruz); and green fluorescent protein (GFP) (Invitrogen). Labeling of dividing cells with 5-bromo-2Ј-deoxyuridine (BrdU) was performed by administering BrdU (50 mg/kg) to pregnant animals 2 hours before sampling of embryos. Staining was visualized with secondary antibodies conjugated with Alexa Fluor 488, 555, 568, 594 and 633 (Invitrogen), and images were obtained using Zeiss LSM-510 confocal microscope or Apotome as described previously Parras et al., 2007) .
Reverse transcriptase polymerase chain reaction (RT-PCR) and in situ hybridization
The expression of Ascl3 and Ascl5 in the developing spinal cord was examined by RT-PCR and in situ hybridization. The following primers were used to obtain cDNAs encoding the predicted full-length open reading frames of Ascl3 and Ascl5 (sequences corresponding to the initiation and termination codons are underlined): Ascl3, 5Ј-GAAACGATGGACACCA -GA AGC-3Ј and 5Ј-CTGATTCAAATGACTCTCAGAG-3Ј; and Ascl5, 5Ј-CATTATGAACAGTAACT-3Ј and 5Ј-GCCAGATCAAAGGCTGGGTT-3Ј. cDNAs reverse transcribed from total RNAs isolated from embryonic (E)10.5 and E16.5 mouse spinal cords were used as templates. The identity of PCR products was verified by sequencing. These cDNAs were used for in situ hybridization as described previously (Mizuguchi et al., 2001) .
Cell culture
Neurosphere culture and infection of recombinant retroviruses were performed as described previously . The titer of viruses was adjusted to infect ~70% of total cells in culture. In double infection experiments, conditions were established for each combination of two different viruses to ensure that more than 85% of GFP + cells coexpressed two transgenes simultaneously. The expression level of transgene products in infected cells was examined by analyzing digital images captured by CCD camera (Hamamatsu Photonics C5810) using Image J software.
To examine the time course of differentiation of OLPs, spinal cords between the upper and lower limb levels were collected from embryos and pups between E14.5 and postnatal (P) 0. Isolated tissue stumps were dissociated and subjected to immunostaining as described previously (Ohori et al., 2006) . Cell nuclei were stained with 4Ј,6-diamidino-2-phenylindole (DAPI) (100 g/ml; Sigma-Aldrich).
To examine differentiation of oligodendrocytes in vitro, spinal cord cells collected from Ascl1 -/embryos and their wild-type littermates at E16.5 and E18.5 were seeded at a density of 2ϫ10 4 cells/ml and cultured for 7 or 14 days. In some cases, thyroid hormone (TH) (triiodothyronine, 30 ng/ml; Sigma-Aldrich) was added to the culture. To expand OLPs in culture, the cells were first grown for 7 days in the presence of fibroblast growth factor 2 and epidermal growth factor (20 ng/ml for each, Peprotech), and subsequently maintained for additional 4 days without growth factors.
RESULTS
Expression of Ascl1 in OLPs at late embryonic stages
Our previous study has shown that Ascl1 expression in OLPs occurs transiently at the time when they are specified in the VZ . Its expression pattern at later stages, however, has not yet been examined in details. Thus, we first followed the developmental time course of Ascl1 expression in the rat spinal cord.
At E14.5, Olig2 + and Nkx2-2 + cells scattered in the spinal cord did not express Ascl1 at a detectable level, except for those in and adjacent to the VZ (see Sugimori et al., 2007) . The majority of them were positive for O4 and PDGFR␣, and thus considered to be OLPs (Fu et al., 2002; Liu and Rao, 2004; Danesin et al., 2006; Sugimori et al., 2007) . From E16.5 onwards, however, Olig2 + and Nkx2-2 + cells beneath the pial surface began to express Ascl1. In particular, the majority of Olig2 + (95%, 112/118 cells examined) and Nkx2-2 + (58%, 88/153) cells were Ascl1 + near the dorsal and ventral midline areas and the lateral margin of the MZ (Fig. 1A , boxed areas and inset, Fig. 1B,C ). In the same areas, 68% (131/194) of Olig2 + cells expressed Nkx2-2, and, conversely, 92% (131/142) of Nkx2-2 + cells were Olig2 + (Fig. 1D ).
At E18.5, the frequency of co-expression of Ascl1, Olig2 and Nkx2-2 increased in both inner and outer parts of the MZ (Fig. 1E-H ). Yet, OLPs that just began to leave the VZ at this late stage did not co-express Olig2 and Nkx2-2, and remained negative for Ascl1 ( Fig. 1I , and data not shown). At E20.5 and P0, however, the majority of OLPs appeared to co-express these transcription factors throughout the MZ ( Fig. 2A -D,I,J). Following their co-expression, the first population of GalC + and MBP + oligodendrocytes emerged at E20.5 ( Fig To further examine the relationship between Ascl1 expression and OLP development, we used Ascl1::GFP mice in which GFP expression is driven by the Ascl1 locus on a transgene (Gong et al., 2003) . In this reporter line, GFP protein sustains longer than endogenous Ascl1 so that progeny of Ascl1 + progenitors can be transiently marked as GFP + cells . In fact, more GFP + cells than Ascl1 + cells were detected in Ascl1::GFP mice at E16.5, the stage when both neurons and OLPs are generated ( Fig.  3A -AЉ) (Helms et al., 2005; Mizuguchi et al., 2006; Sugimori et al., 2007) . Many of these GFP + cells, especially those in the dorsal MZ, were negative for PDGFR␣, a marker for migrating OLPs (Fig. 3A -AЉ). Likewise, GFP expression overlapped with PDGFR␣ and Ascl1 in some, but not all cells in the VZ ( Fig. 3B -BЉ,E,F-FЉ). These GFP + /PDGFR␣cells are likely to be neurons and neuronal progenitors. Importantly, many PDGFR␣ + cells in the MZ expressed GFP ( Fig. 3B-DЉ) . The vast majority of PDGFR␣ + cells were GFP + in the ventral half of the MZ (Fig. 3D -DЉ, arrowheads), whereas a significant fraction of PDGFR␣ + cells were negative for GFP in the dorsal MZ ( Fig. 3C -CЉ, arrows). These dorsal GFP -/PDGFR␣ + cells might have derived from Ascl1progenitors or downregulated GFP during migration. Nevertheless, most of the PDGFR␣ + cells detected near the pial surface were GFP + in both the ventral and dorsal aspects of the spinal cord, and some of them expressed
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Development 135 (7) endogenous Ascl1 ( Fig. 3G-HЉ) . These results demonstrate that Ascl1 expression occurs in a significant fraction of OLPs late in development.
Temporal correlation between Ascl1 and OLP differentiation
We next used dissociated culture to quantify the frequency of coexpression of Ascl1 with other oligodendrocyte markers. As observed in sections, the total numbers of Ascl1 + , Olig2 + and Nkx2-2 + cells markedly increased between E18.5 and E20.5, which occurred in parallel to the emergence of MBP + and GalC + oligodendrocytes ( Fig. 4A,B ). At E18.5, 89% of Nkx2-2 + cells and 63% of Olig2 + cells were NG2 + OLPs (Fig. 4D ). Yet, a significant fraction of Nkx2-2 + cells remained Olig2 -, and many Olig2 + cells were Nkx2-2at this stage. At E20.5, however, a higher fraction of cells co-expressed Olig2 and Nkx2-2. In parallel to their co-expression, the percentage of Ascl1 + cells in Olig2 + and Nkx2-2 + cells also increased. We could not directly determine the number of triple-positive cells for technical reasons, and therefore performed a series of double staining to estimate the number of triple-positive cells (Fig. 4C , parts a-c, D). Their estimated number remained small until E18.5 ( Fig. 4A ). At E20.5, however, more than half of total Olig2 + cells were estimated to be Ascl1 + /Nkx2-2 + , and about twothirds of the Nkx2-2 + cells were considered to be Ascl1 + /Olig2 + . Moreover, the majority of NG2 + , GalC + and MBP + cells expressed these markers. At P0, a significant fraction of Olig2 + cells became negative for Ascl1 and Nkx2-2 ( Fig. 2I, asterisks; Fig. 4D ). These cells could become astrocytes at postnatal stages (Masahira et al., 2006; or remain as undifferentiated OLPs up to adulthood (Yamamoto et al., 2001; Kitada and Rowitch, 2006; Ohori et al., 2006) . Moreover, many MBP + cells became negative for Ascl1 at 1273 RESEARCH ARTICLE Ascl1 in oligodendrocyte development this stage (Fig. 4D ). This could be because Ascl1 expression in myelin + cells is transient or, alternatively, because a separate population of oligodendrocytes emerges from Ascl1-negative OLPs postnatally. In summary, these results demonstrate a temporal correlation between the co-expression of Ascl1 with Olig2 and Nkx2-2, and terminal differentiation of oligodendrocytes.
Recovery of OLPs in late development in Ascl1 -/mutant spinal cords
We next examined late-stage OLP development in Ascl1 -/mutant mice. Despite a significant reduction of OLPs at early stages in the mutant , we found no obvious difference in the density or distribution pattern of Olig2 + and Nkx2-2 + cells between wild type and Ascl1 -/spinal cords at E18.5 or P0 ( Fig.  6A ,E; data not shown). In fact, the numbers of Olig2 + and Nkx2-2 + cells isolated from E18.5 mutants were similar to those in the wild type (1.85±0.22ϫ10 5 Olig2 + cells per spinal cord, corresponding to 103±12% of the wild-type level; 1.54±0.19ϫ10 5 Nkx2-2 + cells and 101±12%, n=3). The majority of these cells were NG2 + , PDGFR␣ + and Sox10 + , indicating that they retained the characteristics of OLPs.
To follow the recovery of OLPs in Ascl1 -/mutants, we examined earlier stages. In our previous study , we detected a significant reduction (60-90%) in the number of OLPs in both the VZ and MZ at E12.5 and E14.5, the stages when early OLPs are generated in the ventral spinal cord. Consistent with this, the number of NG2 + OLPs in the MZ remained smaller in Ascl1 -/embryos compared with the wild type at E14.5 (49.2±12.3%, n=3) and E16.5 (57.7±8.5%). This mutant phenotype is likely to be attributable to a specification defect, but attenuated proliferation of specified OLPs could also underlie the observed reduction. However, their number in and adjacent to the VZ, which were thought to reflect OLPs newly generated at these late stages, was comparable (15±2 and 17±3 NG2 + cells per section in the wild type and mutant, respectively, at E14.5, and 17±2 and 18±4 cells at E16.5, n=4-6 sections at the brachial level per embryos and three embryos examined). A similar recovery was observed for Olig1 + and Nkx2-2 + cells (data not shown). These cells were detected not only in the ventral but also in the dorsal VZ as has been shown in previous studies (Cai et al., 2005; Vallstedt et al., 2005; Fogarty et al., 2005; Sugimori et al., 2007) (data not shown). Thus, OLP generation was defective only at early stages when they were preferentially produced in the ventral spinal cord. The number of OLPs recovered at later stages in Ascl1 mutants, probably because of continuous production of OLPs in multiple progenitor domains over a prolonged period late in development.
The above results suggest that molecules other than Ascl1 promote OLP specification Ascl1 -/mice. We hypothesized that HLH factors related to Ascl1 exert such a function. In fact, we found that two Ascl1-related genes, Ascl3 and Ascl5 (Mouse Genome Informatics: http://www.informatics.jax.org/) are expressed in the developing spinal cord at both E10.5 and E16.5 ( Fig. 5A ). At E10.5, the expression of Ascl3 and Ascl5 mRNAs was detected in both the dorsal and ventral aspects of the VZ, but excluded from the Olig2 + motoneuron progenitor domain (pMN), similarly to Ascl1 (Fig. 5B-D) . We also examined the activity of Ascl3 and Ascl5 in vitro. Our previous study has shown that Ascl1 promotes both neurogenesis and oligodendrogenesis in E13.5 spinal cord-derived multipotent progenitors . Under the same conditions, retrovirus-mediated overexpression of Ascl3 and Ascl5 also promoted differentiation of TuJ1 + neurons and O4 + oligodendrocytes at the expense of GFAP + astrocytes (Fig. 5E-G) .
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Defect in oligodendrocyte differentiation in
Ascl1 -/mice We next asked whether Ascl1 plays any role in differentiation of oligodendrocytes late in development. As described above, the numbers of Olig2 + and Nkx2-2 + cells were similar between the wild type and mutant at E18.5. Staining for activated caspase 3 and labeling of dividing cells with BrdU did not detect any significant difference in the rate of cell proliferation or death between the wildtype and mutant spinal cords. Nevertheless, Ascl1 -/spinal cords showed a severe defect in myelin protein expression at birth. In the wild type, oligodendrocytes expressing CNP, MAG and MBP were detected at P0 in the ventrolateral and dorsomedial outer layer, which corresponded to the forming white matter ( Fig. 6A-D,  arrowheads) . In Ascl1 -/mutants, however, only a few myelin + oligodendrocytes were found in the corresponding regions ( Fig. 6E-H) . Quantitative analyses demonstrated a more than 80% reduction of myelin + oligodendrocytes in Ascl1 -/mice (Fig. 5I) . Ascl1 -/mice die at birth, and therefore differentiation of Ascl1 -/-OLPs was examined in vitro. Cells isolated from E18.5 spinal cords were cultured in the presence and absence of thyroid hormone (TH) to stimulate oligodendrocyte differentiation (Kondo and Raff, 2000a) . When NG2 + OLPs undergo terminal differentiation, they first become NG2 + /GalC + intermediate cells, and subsequently differentiate into NG2 -/GalC + and MBP + oligodendrocytes. In the wild-type culture, a significant fraction of cells was GalC + at day 1 after plating (DAP1) (5.9±1.5% of total cells, n=3), and about a half of them (49±13%) had already proceeded to the NG2 -/GalC + state (Fig. 6J ). In the mutant culture, however, GalC + cells were smaller in percentage, and the majority of them (89±11%) remained as NG2 + /GalCcells (Fig. 6K) . Likewise, 3.6±0.8% (n=3) of wild-type cells already expressed MBP at DAP1, and their percentage significantly increased at DAP7 (Fig. 6L,N) . MBP + cells were further increased about twofold (2.4±0.5-fold) by treatment with TH ( Fig. 6N) . By contrast, few cells were MBP + in the mutant culture at DAP1, and a much lower percentage of cells were MBP + cells at DAP7 (Fig. 6M,N) . Their percentage remained lower in the mutant culture (4.3±0.8%) than in the wild type (14.5±2.9%) at DAP14. Moreover, TH-dependent increase of MBP + cells in the mutant culture (1.4±0.3-fold compared with untreated culture) was significantly smaller than that in the wild-type culture (P<0.05, n=3), suggesting a poor responsiveness of mutant cells to TH. Cells from heterozygous mice (Ascl1 +/-) did not show such a defect (data not shown). During the course of culture, the percentage of Olig2 + cells among total cells did not significantly differ between the wildtype and mutant cells (16.7±4.5% for the wild type and 15.8±2.9% for the mutant at DAP7). Thus, a loss of OLPs during culture is unlikely to account for the differentiation defect of mutant cells. These results suggest that the severe loss of myelin proteinexpressing cells in the mutant is attributable to attenuated or delayed differentiation of OLPs.
Defect in the co-expression of Olig2 and Nkx2-2 in Ascl1 -/-OLPs
We next asked whether the observed defect in Ascl1 -/mutants is related to the co-expression of Olig2 and Nkx2-2. At E16.5, many Olig2 + cells were Nkx2-2 + in the ventral white matter of the wildtype spinal cord (Fig. 7A, arrowheads) . By contrast, only a few double-positive cells were detected in the corresponding region of the mutant. We further examined the co-expression pf Olig2 and Nkx2-2 in vitro. Proliferative cells were enriched in culture of E16.5 spinal cords by treatment with growth factors for 7 days. At the time of growth factor withdrawal (DAP7), 57.6±15.7% (n=3) of the total cells were Olig2 + . Most of these Olig2 + cells (> 95%) were NG2 + and Sox10 + , but few of them were Sox2 + (< 0.5%), indicating that Olig2 + OLPs were enriched in this culture. At this stage of culture, only a small fraction of Olig2 + cells were Nkx2.2 + in both wild-type and mutant cultures (Fig. 7B ). However, when the culture was continued for additional 4 days (DAP11), many Olig2 + cells became Nkx2-2 + in the wild-type culture, and the percentage of Olig2 + /Nkx2-2 + cells among total cells increased from 1.7±0.8% to 18.1±1.8% (P<0.01). By contrast, a much smaller fraction of Olig2 + cells became Nkx2-2 + in culture of Ascl1 -/cells. The percentage of Olig2 + cells among total cells remained similar between the wildtype and mutant cultures at DAP11 (26.2±2.3% and 28.5±5.1%, respectively), and thus the loss of Olig2 + cells did not account for the lack of co-expression of Nkx2-2. These results suggest that the induction of Nkx2-2 expression is impaired in Ascl1 -/-Olig2 + cells.
Nevertheless, 87.7±6.9% (n=3) of Olig2 + cells acutely isolated from E18.5 mutants co-expressed Nkx2-2 ( Fig. 7C ). Thus, the defect observed in vitro is likely to reflect a delay of the expression of Nkx2-2.
We also asked whether Ascl1 is involved in the maintenance of co-expression of Olig2 and Nkx2-2. The vast majority of Olig2 + cells isolated from E18.5 embryos co-expressed Nkx2-2 ( Fig. 7C) . Moreover, 84.6±8.6% of wild-type Olig2 + cells were Ascl1 + at this stage. The high percentage of co-expression Nkx2-2 in Olig2 + cells was maintained for 7 days in the wild-type culture, whereas only about a half of Ascl1 -/-Olig2 + cells remained Nkx2-2 + . However, most Nkx2-2 + cells remained Olig2 + (>90%) at both DAP1 and DAP7, and the number of Olig2 + cells did not significantly differ between the wild-type and mutant cultures (data not shown). Thus, mutant Olig2 + OLPs were defective in maintaining the expression of Nkx2-2. These results demonstrate that one of the actions of Ascl1 in late-stage OLPs is to properly induce and maintain the coexpression of Olig2 and Nkx2-2.
Collaborative actions of Ascl1, Olig2 and Nkx2-2
We next performed gain-of-function studies using neurosphere culture. Multipotent progenitors from E13.5 spinal cords were infected with GFP retroviruses that expressed Olig2, Nkx2-2 and Ascl1 either alone or in combination. Although the expression level of endogenous and exogenous factors varied in individual cells, virusmediated expression conferred about the same or a two-fold higher level of respective transcription factors compared with endogenous proteins (Fig. 8A-D) . In neurosphere culture, specified OLPs were first detected as NG2 + cells, and they subsequently differentiated into GalC + oligodendrocytes (Fig. 8E,F) . We first compared the percentages of NG2 + and GalC + cells among virus-infected cells (Fig. 
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Development 135 (7) 8G,H). Consistent with previous reports (Zhou et al., 2001; Sun et al., 2001; Liu et al., 2007) , both Olig2 and Nkx2-2 increased the fraction oligodendrocyte lineage cells among total cells. Olig2 increased both NG2 + OLPs and GalC + oligodendrocytes, whereas Nkx2-2 increased NG2 + but not GalC + cells. Like Olig2, Ascl1 increased both NG2 + and GalC + cells. Thus, each of these transcription factors retained the ability to promote OLP specification. These effects were not observed in GFPcells within the same culture (data not shown), indicating their cell-autonomous actions. The rate of cell death did not significantly differ between cultures infected with different viruses, indicating that elimination of cells with specific phenotypes is unlikely to account for the observed effects. To distinguish their actions on the early specification and late maturation steps, we next measured the shift from NG2 + /GalC -OLPs to NG2 -/GalC + oligodendrocytes among total oligodendrocyte lineage cells (defined as NG2 + and/or GalC + cells) ( Fig. 9A-C) . In control virus-infected culture, only a small fraction of GFP + cells (3.9±2.3%, n=4) differentiated into cells in the oligodendrocyte lineage. Yet, 57.4% of them proceeded to the mature NG2 -/GalC + stage (Fig. 9D) , and most of them expressed endogenous Olig2, Nkx2-2 and Ascl1 (data not shown). By contrast, this NG2 -/GalC + fraction was much smaller in Olig2-and Nkx2-2-virus infected culture (4.4% and 18.7%, respectively, P<0.01), despite a significant increase of oligodendrocyte lineage cells among total cells (Fig. 9D) . Moreover, their co-overexpression did not stimulate the shift to NG2 -/GalC + cells: the vast majority of cells remained as NG2 + /GalCcells even after prolonged culture (data not shown). Given that both Olig2 and Nkx2-2 are expressed in mature oligodendrocytes in vivo, it is unlikely that their virus-mediated sustained expression accounted for attenuated differentiation. Thus, although the co-expression of Olig2 and Nkx2-2 coincides with the emergence of myelin + oligodendrocytes in vivo, increased expression of each of these factors or their combination was not sufficient to promote differentiation of OLPs into oligodendrocytes.
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Development 135 (7) In Ascl1 virus-infected culture, the majority remained as NG2 + /GalC + intermediate cells (69.5%), and only a small fraction (11.2%) proceeded to NG2 -/GalC + cells (Fig. 9B,D) . Importantly, the combinatorial expression of Ascl1 and Olig2 markedly stimulated this transition: 51.2% of total oligodendrocyte lineage cells become NG2 -/GalC + cells. Similarly, a significantly higher percentage (34.8%) became NG2 -/GalC + cells in culture co-infected with Ascl1 and Nkx2-2 viruses. Given that overexpression of Ascl1 alone promoted the generation of NG2 + OLPs that expressed endogenous Olig2 or Nkx2-2, these results suggest that simultaneous elevated expression of Ascl1 and Olig2 or Ascl1 and Nkx2-2 is necessary for promoting the transition from OLPs to oligodendrocytes.
DISCUSSION
Role of Ascl1 in late-stage oligodendrocyte development
We have demonstrated that the HLH transcription factor Ascl1 plays an important role in late-stage development of oligodendrocytes in the spinal cord. Although Olig2 + and Nkx2-2 + OLPs migrating in the MZ did not express Ascl1 at early stages, they became Ascl1 + around the perinatal stage in the forming white matter. This late Ascl1 expression coincided with the co-expression of Olig2 and Nkx2-2. Moreover, Ascl1 -/mutant Olig2 + OLPs showed a defect in the induction and maintenance of co-expression of Nkx2-2. The subsequent expression of myelin proteins was also attenuated in the mutant at birth. In vitro, Ascl1 promoted differentiation of OLPs into oligodendrocytes in collaboration with Olig2 and Nkx2-2.
It is noteworthy that Ascl1 expression is biphasic during the course of oligodendrocyte development. This is in sharp contrast with the sustained expression of other transcription factors involved in oligodendrogenesis. For example, the expression of Olig2, Nkx2-2, Sox5 and Sox9 begins early in multipotent progenitors and continues in OLPs during late embryogenesis (Qi et al., 2001; Lu et al., 2002; Takebayashi et al., 2002; Stolt et al., 2003; Stolt et al., 2006) . Olig1, Sox8 and Sox10 are induced in specified OLPs and maintained in mature oligodendrocytes (Lu et al., 2002; Zhou and Anderson, 2002; Takebayashi et al., 2002; Stolt et al., 2002; Stolt et al., 2004) . By contrast, Ascl1 expression is transient at the time of OLP specification, and, once specified, OLPs remain negative for Ascl1 until the onset of their terminal differentiation.
How does Ascl1 control late-stage oligodendrocyte differentiation? Given that the co-expression of Olig2 and Nkx2-2 is impaired in Ascl1 -/mutants, the severe reduction of myelin-expressing oligodendrocytes at birth could be attributable, at least in part, to this defect. In fact, the reported phenotypes of Nkx2-2 -/mice are reminiscent of those observed in Ascl1 -/mutants (Qi et al., 2001) . However, our preliminary study suggests that the expression of Olig2 or Nkx2-2 is not under direct transcriptional control by Ascl1 (S.M. and M.N., unpublished). Our data also suggest that Ascl1 has a role other than their co-expression. Combinatorial overexpression of Olig2 and Nkx2-2 was not sufficient to promote the transition from OLPs to oligodendrocytes, whereas the combination of Ascl1 with Olig2 or Nkx2-2 strongly stimulated this maturation step. Moreover, differentiation of MBP + cells was poorly stimulated by TH in culture of Ascl1 -/cells, suggesting that Ascl1 is involved in regulating the responsiveness to TH. Interestingly, a previous study has shown that Ascl1 upregulates expression of the TH receptor TR␤1 in cultured OLPs (Kondo and Raff, 2000a) . These results support the idea that Ascl1 regulates late-stage differentiation of oligodendrocytes at two steps: the co-expression of Olig2 and Nkx2-2, and the subsequent THresponsive myelin gene expression ( Fig. 10) .
Cooperation of Ascl1 with Olig2 and Nkx2-2 in oligodendrocyte development
Ascl1 cooperated with Olig2 and Nkx2-2 to promote differentiation of OLPs into oligodendrocytes. It remains unknown at present what mechanisms underlie their collaborative actions. These transcription factors could cooperatively regulate the same set of downstream genes or, alternatively, control independent sets of genes that, in turn, mediate their collaborative actions. Given that combinatorial overexpression of these transcription factors was required for differentiation of OLPs, their overall expression levels and/or rations could be an important determinant for terminal differentiation of oligodendrocytes. Previous studies have shown that various inhibitory HLH factors negatively regulate myelin gene expression (Gokhan et al., 2005; Liu et al., 2006) . Thus, it could be that the expression of Ascl1, Olig2 and Nkx2-2 needs to reach a certain level to counteract these inhibitors. Moreover, given that they act in both specification and differentiation of oligodendrocytes, additional molecules are likely to cooperate with them at each of these steps. A possible candidate is the Sox family of transcription factors. The reported defects in Sox9 -/-, Sox10 -/and their double mutants are reminiscent of those in Ascl1 -/mice (Stolt et al., 2003; Liu et al., 2007) . Sox10 and Ascl1 have been shown to synergize to activate transcription of a MBP enhancer-driven reporter in vitro (Gokhan et al., 2005; Liu et al., 2006) .
Ascl1-dependent and -independent oligodendrocyte development
Generation of OLPs at early stages is severely impaired in the Ascl1 -/mutant spinal cord . This could be attributable to a defect in either specification or proliferation of early OLPs. The number of Olig2 + and Nkx2-2 + OLPs, however, recovered to the wildtype level around the perinatal stage. These cells expressed PDGFRa, Sox10 and NG2, suggesting that they retained the characteristics of OLPs. Thus, the differentiation defect of Ascl1 -/-OLPs at late stages appears not to be a mere consequence of their early specification defect. It remains possible, however, that mutant OLPs are defective in a manner that is not discernible using commonly used OLP markers, at the time of their specification, and that such an early defect is responsible for impaired differentiation at later stages.
Several lines of evidence support the idea that Ascl1 is required cell-autonomously in oligodendrocytes. Recent studies have provided genetic evidence for the expression of Ascl1 in the RESEARCH ARTICLE Ascl1 in oligodendrocyte development Fig. 10 . Proposed actions of Ascl1 in oligodendrocyte development. In this model, Ascl1 regulates oligodendrocyte development at multiple steps (thick vertical arrows). At early stages, Ascl1 promotes specification of OLPs from multipotent progenitors (MP). At late embryonic and perinatal periods, Ascl1 regulates the coexpression of Olig2 and Nkx2-2, and subsequently cooperates with them to promote differentiation of myelin + oligodendrocytes. oligodendrocyte lineage (Battiste et al., 2007; Parras et al., 2007; Kim et al., 2007) . Moreover, overexpression of Ascl1 stimulated differentiation of oligodendrocytes in a cell-autonomous manner in vitro. Our previous study has also shown that Ascl1 -/mutant cells poorly differentiate into oligodendrocytes when grafted into the wild-type mice (Parras et al., 2004) . These results, however, do not exclude the possibility that Ascl1 also regulates oligodendrogenesis in a non-cell-autonomous manner, i.e. through the regulation of other cell lineages.
It should also be noted that the defect in oligodendrocyte differentiation late in development was not complete in Ascl1 -/mutants. It remains unknown whether this is simply due to delayed differentiation of all OLPs or to the inability of a subpopulation of OLPs to differentiate. Our previous studies have shown a partial or transient defect in OLP specification in the mutant brain . Wang et al. (Wang et al., 2001) reported that OLPs isolated from postnatal optic nerves of Ascl1 -/mice show no noticeable defect in vitro. Thus, it is likely that there are Ascl1dependent and -independent oligodendrocytes. The latter could originate from Ascl1 non-expressing cells or, alternatively, they could derive from Ascl1-expressing cells by Ascl1-independent mechanisms. We found that the Ascl1-related factors Ascl3 and Ascl5 are expressed in the developing spinal cord, and that like Ascl1, they are capable of promoting oligodendrogenesis in vitro. The redundant function of these Ascl factors may explain partial defects in both neurogenesis and oligodendrogenesis in many areas of the developing CNS in Ascl1 -/mutants (Parras et al., 2002; Casarosa et al., 1999; Torii et al., 1999; Helms et al., 2005; Mizuguchi et al., 2006; Sugimori et al., 2007; Parras et al., 2007) . Further understanding of the roles of Ascl1 and related HLH factors in oligodendrocytes should provide better insights into the mechanisms underlying development of this important glial cell type in the vertebrate CNS.
